Question | Discussion | References | CME Credit

Case 4: References

  1. Smith DE, Walker BD, Cooper DA, Rosenberg ES, Kaldor JM. Is antiretroviral treatment of primary HIV infection clinically justified on the basis of current evidence? AIDS. 2004;18:709-18.
    [The following link will open in a new window. PubMed Abstract]
  2. Kinloch-De Loes S, Hirschel BJ, Hoen B, et al. A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med. 1995;333:408-13.
    [The following link will open in a new window. PubMed Abstract]
  3. Malhotra U, Berrey MM, Huang Y, et al. Effect of combination antiretroviral therapy on T-cell immunity in acute human immunodeficiency virus type 1 infection. J Infect Dis. 2000;181:121-31.
    [The following link will open in a new window. PubMed Abstract]
  4. Lafeuillade A, Poggi C, Tamalet C, Profizi N, Tourres C, Costes O. Effects of a combination of zidovudine, didanosine, and lamivudine on primary human immunodeficiency virus type 1 infection. J Infect Dis. 1997;175:1051-5.
    [The following link will open in a new window. PubMed Abstract]
  5. Perrin L, Rakik A, Yerly S, Baumberger C, Kinloch-de Loes S, Pechere M, Hirschel B. Combined therapy with zidovudine and L-697,661 in primary HIV infection. AIDS. 1996;10:1233-7.
    [The following link will open in a new window. PubMed Abstract]
  6. Smith DE, Kaufmann GR, Kahn JO, et al. Greater reversal of CD4+ cell abnormalities and viral load reduction after initiation of antiretroviral therapy with zidovudine, lamivudine, and nelfinavir before complete HIV type 1 seroconversion. AIDS Res Hum Retroviruses. 2003;19:189-99.
    [The following link will open in a new window. PubMed Abstract]
  7. Berrey MM, Schacker T, Collier AC, et al. Treatment of primary human immunodeficiency virus type 1 infection with potent antiretroviral therapy reduces frequency of rapid progression to AIDS. J Infect Dis. 2001;183:1466-75.
    [The following link will open in a new window. PubMed Abstract]
  8. Rizzardi GP, Harari A, Capiluppi B, et al. Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy. J Clin Invest. 2002;109:681-8.
    [The following link will open in a new window. PubMed Abstract]
  9. Markowitz M, Jin X, Hurley A, et al. Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination. J Infect Dis. 2002;186:634-43.
    [The following link will open in a new window. PubMed Abstract]
  10. Rosenberg ES, Altfeld M, Poon SH, et al. Immune control of HIV-1 after early treatment of acute infection. Nature. 2000;407:523-6.
    [The following link will open in a new window. PubMed Abstract]
  11. Oxenius A, Price DA, Easterbrook PJ, et al. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. Proc Natl Acad Sci U S A. 2000;97:3382-7.
    [The following link will open in a new window. PubMed Abstract]
  12. Cossarizza A, Poccia F, Agrati C, et al. Highly active antiretroviral therapy restores CD4+ Vbeta T-cell repertoire in patients with primary acute HIV infection but not in treatment-naive HIV+ patients with severe chronic infection. J Acquir Immune Defic Syndr. 2004;35:213-22.
    [The following link will open in a new window. PubMed Abstract]
  13. Lafeuillade A, Poggi C, Hittinger G, Counillon E, Emilie D. Predictors of plasma human immunodeficiency virus type 1 RNA control after discontinuation of highly active antiretroviral therapy initiated at acute infection combined with structured treatment interruptions and immune-based therapies. J Infect Dis. 2003;188:1426-32.
    [The following link will open in a new window. PubMed Abstract]
  14. Kaufmann DE, Lichterfeld M, Altfeld M. Limited durability of viral control following treated acute HIV infection. PLoS Med. 2004;1:e36.
    [The following link will open in a new window. Pub Med Abstract ]
  15. Altfeld M, Allen TM, Yu XG, et al. HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus. Nature. 2002;420:434-9.
    [The following link will open in a new window. PubMed Abstract]
  16. Dybul M, Hidalgo B, Chun TW, et al. Pilot study of the effects of intermittent interleukin-2 on human immunodeficiency virus (HIV)-specific immune responses in patients treated during recently acquired HIV infection. J Infect Dis. 2002;185:61-8.
    [The following link will open in a new window. PubMed Abstract]
  17. Garber DA, Silvestri G, Barry AP, et al. Blockade of T cell costimulation reveals interrelated actions of CD4+ and CD8+ T cells in control of SIV replication. J Clin Invest. 2004;113:836-45.
    [The following link will open in a new window. PubMed Abstract]
  18. Deeks SG, Walker BD. The immune response to AIDS virus infection: good, bad, or both? J Clin Invest. 2004;113:808-10.
    [The following link will open in a new window. PubMed Abstract]
  19. Yerly S, Vora S, Rizzardi P, et al. Acute HIV infection: impact on the spread of HIV and transmission of drug resistance. AIDS. 2001;15:2287-92.
    [The following link will open in a new window. PubMed Abstract]
  20. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med. 2002;347:385-94.
    [The following link will open in a new window. PubMed Abstract]
  21. Simon V, Vanderhoeven J, Hurley A, et al. Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals. AIDS. 2002;16:1511-9.
    [The following link will open in a new window. PubMed Abstract]
  22. Grant RM, Hecht FM, Warmerdam M, et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA. 2002;288:181-8.
    [The following link will open in a new window. PubMed Abstract]
  23. Tang JW, Pillay D. Transmission of HIV-1 drug resistance. J Clin Virol. 2004;30:1-10.
    [The following link will open in a new window. PubMed Abstract]
  24. Bartlett JG, Lane HC, and the Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents (a Working Group of the Office of AIDS Research Advisory Council). Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. December 1, 2007. Available at:
    [The following link will open in a new window. AIDSinfo - Accessed December 10, 2007]
  25. Stekler J, Maenza J, Stevens C, et al. Abacavir hypersensitivity reaction in primary HIV infection. AIDS. 2006;20:1269-74.
    [The following link will open in a new window. PubMed Abstract]

[Back to Case 4 Question | Back to Discussion]

CME Credit | Back to Top